|Bid||35.20 x 800|
|Ask||35.30 x 1000|
|Day's Range||33.30 - 35.56|
|52 Week Range||19.38 - 87.24|
|Beta (5Y Monthly)||2.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The market's "man with a hammer" attitude toward pharmaceutical stocks has arguably created some truly compelling buying opportunities for patient investors, however. Here is a brief overview of eight pharmaceutical stocks (listed alphabetically) that have fallen way too far this year, making them top buys leading into 2022. Adaptimmune Therapeutics (NASDAQ: ADAP), a cellular immunotherapy company, has so far lost 47.4% of its value relative to its 52-week high in 2021.
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
Shares of Axsome Therapeutics (NASDAQ: AXSM) lost 9.75% of their value through Thursday's closing bell this week, according to data from S&P Global Market Intelligence. The biotech's shares are currently well off of their 52-week highs due to a regulatory delay for its experimental major depressive disorder drug AXS-05. What's important to understand is that this regulatory hiccup reportedly centers around two issues with the company's analytical methods in the Chemistry, Manufacturing, and Controls section of the New Drug Application submitted to the Food and Drug Administration (FDA).